OZONE RESEARCH GROUP INC.

Dear People of the World:

We would like to introduce ourselves as the the Medical Ozone center, First to Provide Ground - Breaking Therapy in Treatment and Prevention of Coronary Artery Disease. We make excellence the only acceptable standard of your care.

RHP/EBOO - has set a benchmark, by its self-recognition in playing the key role in the treatment and Prevention of Coronary Artery Disease. No Cardiologist, Medical Professional, or Coronary Heart Disease Patient can afford to ignore this vital role of RHP/EBOO Medical Ozone Generators.

As a leader in the discovery, development, manufacture, training, certification and marketing of certified RHP/EBOO Ozone Units, we are committed to improving health and well-being through innovative treatment, products and services. We share the medical world's goal of bringing safer and more effective products to the market as promptly as possible.

Before we introduce our treatment, products and services, allow us to give a brief about ozone therapy which began in 1870 in Germany and now approved in more than 25 countries all around the world including Germany, Italy, Japan, Austria, Switzerland, Spain, Russia, UK, India, Cuba and some states in the US plus many more. There are over 2,000 Medical Ozone clinics in Europe alone.

The therapeutic use of Medical Ozone has an excellent safety record and no toxic effects have been observed from clinical use. The use of Medical Ozone as a healing adjunct is well established and is being vigorously pursued by many scientists and clinicians. The benefits are predictable and without side effects. As technology advances, undoubtedly new techniques will enlarge the scope of the effective use of this versatile modality.

Now let us introduce our main topic-RHP/EBOO Medical Ozone Generators, the therapeutic ozoniser, an equipment that produces automatically different ozone concentrations in continuous and reproducible ways in all of Medical Ozone's therapeutic range.

It can be used in all ozone medical therapies known at present, for example, optic neuropathy, chronic glaucoma, cochleovestibular syndrome, retinitis pigmentosa, senile dementia, sickle cell anemia, sepsis prevention, arthorosis, obliterant arteriopathy, ulcers of the limb, diabetic foot, radiological contrast in diaphragmatic angiography. In general, in the specialties of ophthalmology, geriatrics, orthopedics, angiology and internal medicine.

As the function implies, RHP/EBOO generates Medical Ozone upon introduction of medical oxygen into the unit. Our procedure, known as RHP (Recuiculatory Haemoperfusion) and EBOO (Extracorporeal Blood Oxygenation and Ozonation) is similar to haemodylisis. In this case, RHP/EBOO is born as remedy to many cardiological problems, without undergoing the threatening high risk, painful, expensive and complicated procedures of surgery.

Specialized ozone therapy centers, on administrating the non- invasive therapy RHP/EBOO to severe coronary artery disease patients and have found amazing results.

Through years of extensive research, we have developed an apparatus called RHP/EBOO that facilitates to treat 3 to 4 liters of blood with medical ozone in extracorporeal circulation for a period 60 to 90 minutes of patients with coronary heart disease. RHP/EBOO has proven to be second to none in delivering its role in the procedural assay of safe straight to the heart.

To achieve satisfactory result, one has to undergo 5 to 35 hours therapy depending on the state of the disease.

RHP/EBOO is performed by withdrawing venous blood and the same blood is infused into an oxygen-ozone gas exchange filter in and upward direction, using a specialized guideline with a computerized peristaltic pump controlling the rate of withdrawal. Medical ozone from the unit is introduced into this hydrophobic and ozone resistant gas exchange filter in the opposite direction from top going downwards and ozonation of blood begins. To avoid coagulation during the process of RHP/EBOO treatment, heparinazation of the blood is done but not absolutely necessary as there are other means, just before the blood is infused into the filter. After passing through the oxygen-ozone gas exchange filter, treated blood is re-infused in to the patient. Upon establishment of extracorporeal circuit, the withdrawal rate will be increased to a range of 60-80 ml per minute, depending on the condition of the patient.

RESULTS

It has been established by various scientific researchers that reinfusion oxygenated and ozonated blood enhances the release of nitric oxide and interleukin-8 in the human endothelial cells (the layer of cells lining on the artery wall).

Achieved results of the therapy in general from various conditions of patients shows:

1. Improved Vasodilatation (stretching of a vessel/arteriole beyond its normal dimension leading to increased blood flow) in ischemic areas.

2. Reduced hypoxia (reduction of oxygen carrying capacity of blood)

3. Induced Neoangiogenesis (formation of new blood vessels) due to enhanced release of nitric oxide.

Now let us introduce SAFE.

SAFE is a device-based therapy intended to remove extra fluid from blood and body ; Simple Access Fluid Extraction (SAFE) as the name implies. Patients with heart failure typically are treated with various medications, including angiotensin-converting enzyme inhibitors, beta-blockers, diuretics, and inotropic drugs. Although these drugs don't stop disease progression, they may reduce symptoms and improve functional capacity. Over time, however, some patients stop responding to these therapies.

SAFE , a process that removes fluid from the intravascular compartment, can help ease symptoms for these patients. It may even help patients respond again to conventional drug therapy.

During SAFE, the patient intravascular fluid remains stable, as fluid shifts from extravascular space that lost from the vessels. This reduces edema and third spacing. But because fluid is not removed from the vascular compartment any faster than it can be recruited from the peripheral tissues, patients do not become hypotensive- the plasma refilling rate is adequate to prevent hypovolemia. The patient's heart rate, blood pressure and serum electrolytes also remain largely unchanged.

In general, SAFE improves the quality of life with the ceasing of anginal pain and increase of functional abilities. We are proud to say that SAFE is a truly high quality Malaysian invention by a team of medical experts and engineers.

We would also like to dedicate our sincere appreciation to the 1998 Nobel Prize Winners in Physiology or Medicine for their discoveries concerning nitric oxide as a signaling molecules in the cardiovascular system- Robert F. Furchgott (SUNY Health Science Center Brooklyn, New York, USA), Louis J. Ignarro (University of California School of Medicine) and Ferid Murad (University of Texas) for their discoveries concerning the role of nitric oxide as a signaling molecule in the cardiovascular system. These medical experts have given us the inspiration and encouragement to come up with our invention SAFE.